Long-acting sustained-release cell scaffold, and preparation method and application thereof

A cell scaffold and slow-release technology, which is applied in the fields of pharmaceutical formulation, medical science, and capsule delivery, can solve the problems of short drug release time, secondary injury, and easy recurrence, and achieve good mechanical tolerance, metabolic activity, and strong Effects of Mechanical Tolerance and Prolonged Drug Release Period

Active Publication Date: 2019-04-12
上海北陆医药科技有限公司
View PDF15 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

This is mainly due to the poor mechanical and bioavailability of the chondrocyte scaffold made by the existing method, which causes the coating layer of the cytokine drug to be easily destroyed, the drug release time is short and the release amount is unstable, and the short The efficacy of the drug leads to problems such as easy recurrence after treatment, and the coating layer of the drug cannot be completely absorbed by the human body, and it will cause secondary damage if it remains in the human body. The above reasons have led to the current drug-loaded cell scaffold technology being used clinically. Arthritis treatment is not effective

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Long-acting sustained-release cell scaffold, and preparation method and application thereof
  • Long-acting sustained-release cell scaffold, and preparation method and application thereof
  • Long-acting sustained-release cell scaffold, and preparation method and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0044] combine Figure 1 to Figure 6 As shown, a long-acting slow-release cell scaffold provided in this embodiment includes drug-cytokine protein 1, silk fibroin 3 and composite protein 4, and the drug-cytokine protein 1 is mixed with silk fibroin 3 The cytokine sustained-release microspheres 2 formed by coating, the complex protein 4 is coated on the outer layer of the cytokine sustained-release microspheres 2, and the silk fibroin 3 is a silk fibroin regulated by calcium salt self-assembly , the complex protein 4 includes gelatin that can escape the immune attack of the body and can be degraded and metabolized by cells; the drug-cytokine protein 1 includes but not limited to basic fibroblast bFGF with a concentration of 0-2 mg / ml, and a concentration of 0 Transforming growth factor beta 1 at 2 mg / ml, transforming growth factor beta 2 at a concentration of 0-2 mg / ml, transforming growth factor beta 3 at a concentration of 0-2 mg / ml and BMP-2 at a concentration of 0-2 mg / ml; ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
concentrationaaaaaaaaaa
concentrationaaaaaaaaaa
Login to view more

Abstract

The invention discloses a long-acting sustained-release cell scaffold, and a preparation method and application thereof. The long-acting sustained-release cell scaffold comprises a drug-cytokine protein, a silk fibroin and a complex protein. The drug-cytokine protein is coated by the silk fibroin to form cytokine sustained-release microspheres; the complex protein coats the outer layers of the cytokine sustained-release microspheres; the silk fibroin is a self-assembled silk fibroin by calcium salt regulation; the complex protein comprises gelatin capable of escaping body immune attack and degradable by cells. According to the preparation method, first the cytokine sustained release microspheres are formed through silk fibroin coating, and then the cytokine sustained release microspheres are coated with the complex protein degradable by cells, so that 3-5 month long-term sustained release of the drugs can be realized; a hydrogel hybrid formed by the complex protein is more mechanicallytolerant than simple collagen and chondroitin sulfate; and the scaffold has good homology, and a long drug sustained release period, so that the cartilage tissue has better mechanical tolerance and metabolic activity during conversion of the scaffold into a cartilage matrix.

Description

technical field [0001] The invention relates to a long-acting slow-release cell scaffold loaded with drug-cytokines protein and its preparation method and application. Background technique [0002] Cell scaffolds, also known as tissue engineering scaffold materials, refer to materials that can be combined with living cells of tissues and implanted into different tissues of organisms, and can replace the functions of tissues according to specific conditions. In order to proliferate and differentiate seed cells, it is necessary to provide a cell scaffold composed of biosoluble materials, which is equivalent to an artificial extracellular matrix. Tissue engineering scaffold materials include: tissue scaffold materials for bone, cartilage, blood vessels, nerves, skin and artificial organs, such as liver, spleen, kidney, bladder, etc. It is an effective means to treat various chronic soft tissue diseases, and its application prospect is broad. [0003] Articular cartilage can re...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61L27/20A61L27/22A61L27/54
CPCA61L27/20A61L27/222A61L27/227A61L27/54A61L2300/252A61L2300/412A61L2300/602A61L2300/622A61L2400/06A61L2430/06C08L89/00C08L5/08
Inventor 贾翠英其他发明人请求不公开姓名
Owner 上海北陆医药科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products